Two risk factors for hypozincemia in diabetic β-thalassemia patients: Hepatitis C and deferasirox.

Two risk factors for hypozincemia in diabetic β-thalassemia patients: Hepatitis C and deferasirox.

<h4>Background and aim</h4>Hypozincemia is a prevalent adverse consequence in diabetes mellitus (DM) and β-Thalassemia patients. We aimed to evaluate the level of serum zinc in β-thalassemia patients with DM and a risk assessment for hypozincemia.<h4>Methods</h4>The study pop...

Full description

Bibliographic Details
Main Authors:	Hadi Darvishi-Khezri, Hossein Karami, Mohammad Naderisorki, Mobin Ghazaiean, Mehrnoush Kosaryan, Amir Mosanejad-Galchali, Aily Aliasgharian, Hasan Karami
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2024-01-01
Series:	PLoS ONE
Online Access:	https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0284267&type=printable

Similar Items

Ferritin thresholds for cardiac and liver hemosiderosis in β-thalassemia patients: a diagnostic accuracy study
by: Hadi Darvishi-Khezri, et al.
Published: (2022-10-01)

Factors Related to Reduced Bone Density in β-Thalassemia Major Patients: Mazandaran Thalassemia Registry
by: Hossein Karami, et al.
Published: (2023-09-01)

Ebselen: A promising therapy protecting cardiomyocytes from excess iron in iron-overloaded thalassemia patients
by: Ghazaiean Mobin, et al.
Published: (2023-07-01)

Amlodipine Therapy in β-Thalassemia Patients: A Systematic Review and Meta-Analysis on Ferritin Levels and Liver MRI T2*
by: Aily Aliasgharian, et al.
Published: (2023-12-01)

First Report of the Electronic Registry of Patients with Beta Thalassemia Major in Mazandaran Province, Iran
by: Mehrnoush Kosaryan, et al.
Published: (2017-07-01)

Co-existence of Phenylketonuria (PKU) and beta-Thalassemia Major in a 16 Years Old Girl: A Case Report
by: Hossein Karami, et al.
Published: (2012-07-01)

Co-existence of Phenylketonuria (PKU) and beta-Thalassemia Major in a 16 Years Old Girl: A Case Report
by: Hossein Karami, et al.
Published: (2012-09-01)

PB2540: HEPATIC SAFETY PROFILE OF DEFERASIROX IN CHILDREN WITH BETA THALASSEMIA MAJOR IN OMAN
by: Shaimaa Almadhani, et al.
Published: (2023-08-01)

In Vitro Hb Production in Β-thalassemia Patients Is Not a Predictor of Clinical Responsiveness to Hydroxyurea
by: Mohammad Reza MAHDAVI, et al.
Published: (2017-06-01)

Two trade names of deferasirox (Osveral® and Exjade®) in reduction of iron overload parameters in major beta-thalassemia patients: A randomized open labeled clinical trial
by: Mohammadreza Rafati, et al.
Published: (2022-01-01)

Evaluation of Hepatic Enzymes in major β-thalassemic Patients using Deferasirox
by: Ahmed Yahya Dallal Bashi, et al.
Published: (2022-12-01)

Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia
by: Pennell, D.J., et al.
Published: (2010)

Stable Luminescent Poly(Allylaminehydrochloride)-Templated Copper Nanoclusters for Selectively Turn-Off Sensing of Deferasirox in β-Thalassemia Plasma
by: Hung-Ju Lin, et al.
Published: (2021-12-01)

Symptomatic Characteristics of Hypozincemia Detected in Long COVID Patients
by: Yui Matsuda, et al.
Published: (2023-03-01)

Comparative analysis of deferasirox and deferiprone iron chelator on the growth pattern of Bengali β-thalassemia major children of West Bengal, India
by: Isita Tripathy, et al.
Published: (2022-09-01)

Clinical and biochemical studies on zinc deficiency (hypozincemia) of goat and sheep
by: Khaleel Zainel Khaleel
Published: (2013-06-01)

Hypozincemia in COVID-19 Patients Correlates With Stronger Antibody Response
by: Wenye Xu, et al.
Published: (2022-01-01)

Co-Inheritance of Heterozygous β<sup>0</sup>-Thalassemia with Single Functional α-Globin Gene: Challenges of Carrier Detection in Pre-Marital Screening Program for Thalassemia
by: Hossein Jalali, et al.
Published: (2022-08-01)

P1511: EFFICACY AND SAFETY OF COMBINATION IRON CHELATION THERAPY WITH DEFERIPRONE AND DEFERASIROX IN PATIENTS WITH Β-THALASSEMIA MAJOR: A SYSTEMATIC LITERATURE REVIEW
by: A. Piga, et al.
Published: (2022-06-01)

Effects of Zinc Acetate Hydrate Supplementation on Renal Anemia with Hypozincemia in Hemodialysis Patients
by: Eiichi Sato, et al.
Published: (2022-10-01)

Use of Deferasirox Film-Coated Tablets in Pediatric Patients with Transfusion Dependent Thalassemia: A Single Center Experience
by: Alkistis Adramerina, et al.
Published: (2022-02-01)

Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials.
by: Sujian Xia, et al.
Published: (2013-01-01)

Retrospective study on the therapeutic efficacy of zinc acetate hydrate administration to patients with hypozincemia-induced dysgeusia
by: Tomoaki Shintani, et al.
Published: (2023-03-01)

Continued improvement and normalization of myocardial T2*in patients with beta-thalassemia major treated with deferasirox (Exjade (R)) for up to 3 years
by: Pennell, D., et al.
Published: (2010)

A T2* MRI prospective survey on heart iron in thalassemia major patients treated with sequential deferipron-desferrioxamine versus deferasirox
by: Borgna-Pignatti Caterina, et al.
Published: (2011-02-01)

Efficacy of deferasirox in patients with thalassaemia major is not affected by a history of hepatitis B OR C
by: Cappellini, M.D., et al.
Published: (2010)

Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload
by: Wu D, et al.
Published: (2018-05-01)

P1451: PUBERTAL DEVELOPMENT OF TRANSFUSION DEPENDENT THALASSEMIA PATIENTS AT THE ERA OF ORAL CHELATION WITH DEFERASIROX: RESULTS OF THE FRENCH NATIONAL REGISTRY NATHALY
by: Mathilde Veneziano, et al.
Published: (2023-08-01)

Renal function in patients with thalassemia major receiving Exjade® dispersible tablets and a new film-coated tablet formulation of deferasirox (Nanojade®)
by: Vahid Falahati, et al.
Published: (2022-01-01)

Comparison of the Effects of Deferasirox (Nanojade®) and Deferoxamine (Desferal®) on Serum Ferritin Level Changes in Major Beta-Thalassemia Patients: A Randomized Clinical Trial
by: saeedeh Khorashadi Zadeh, et al.
Published: (2023-12-01)

Deferasirox, an oral chelator in the treatment of iron overload
by: I. Portioli
Published: (2013-05-01)

Evaluation of Pharmacokinetics and Pharmacodynamics of Deferasirox in Pediatric Patients
by: Laura Galeotti, et al.
Published: (2021-08-01)

Duodenal perforation caused by deferasirox “case report”
by: Mohammmed Al Blooshi, et al.
Published: (2023-07-01)

Deferasirox – a rarer cause of Fanconi syndrome
by: Iman Khan, et al.
Published: (2019-07-01)

A Case Report of Giant Cell Tumor of the Tendon Sheath after Treatment of Germ Cell Tumor of Testicles in a 7-year-old boy
by: Hossin Karami, et al.
Published: (2020-10-01)

Prevalence of alloimmunization in major beta thalassemia in northern Iran (2010)
by: Kosaryan M, et al.
Published: (2014-07-01)

Dental Treatment Needs in Thalassemia Major Patients, Sari, Iran
by: Atena Shiva, et al.
Published: (2019-12-01)

An overview of CYP27B1 enzyme mutation and management: A case report and review of the literature
by: Daniel Zamanfar, et al.
Published: (2023-03-01)

Letter to Editor: Some Comments on "Effects of Zero- and 90-Degree Abduction of Glenohumeral Joint on the Upper Extremity Nerve Conduction Velocity (NCV) in Patients with Diabetes Undergoing Coronary Artery Bypass Graft Surgery"
by: Masaudeh Babakhanian, et al.
Published: (2017-03-01)

Prenatal diagnosis in Islamic countries: A narrative review in 2013
by: Mehrnoush Kosaryan, et al.
Published: (2014-02-01)